Krystal Biotech (KRYS) Tax Provisions (2023 - 2026)
Krystal Biotech (KRYS) posted quarterly Tax Provisions of $11.3 million for Q2 2026, up 33.98% year-over-year from $8.4 million in Q2 2025, and up 105.28% on a QoQ basis from $5.5 million in Q1 2026.
Krystal Biotech (KRYS) Tax Provisions (2023 - 2026) Analysis & Trends
Krystal Biotech has reported Tax Provisions for 4 years, with the latest figure at $11.3 million in Q2 2026.
- Tax Provisions for Q2 2026 came in at $11.3 million, up 33.98% year-over-year; the trailing twelve-month figure through Jun 2026 was -$14.8 million (down 167.33% YoY), and the FY2025 annual result was -$15.4 million, down 347.86% from the prior year.
- Tax Provisions climbed to $11.3 million in Q2 2026, from $5.5 million in the prior quarter.
- Over five years, Tax Provisions peaked at $11.3 million in Q2 2026 and troughed at -$31.4 million in Q3 2025.
- A 4-year average of $964200.0 and a median of $2.8 million in 2024 frame the typical range for Tax Provisions.
- The largest YoY upside for Tax Provisions was 1669.81% in 2025 against a maximum downside of 1307.69% in 2025.
- A 4-year view of Tax Provisions shows it stood at $2.0 million in 2023, then jumped by 57.61% to $3.1 million in 2024, then sank by 108.4% to -$260000.0 in 2025, then jumped by 4450.38% to $11.3 million in 2026.
- Per Business Quant data, the three most recent Tax Provisions figures were $11.3 million in Q2 2026, $5.5 million in Q1 2026, and -$260000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 59.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 75.45 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 267.73 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.31 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.90 Mn |
| 10 | Krystal Biotech | 9.83 Bn | 8.99 Bn | 112.79 Mn | 11.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.31 Mn |
| Mar 31, 2026 | 5.50 Mn |
| Dec 31, 2025 | -260,000.00 |
| Sep 30, 2025 | -31.40 Mn |
| Jun 30, 2025 | 8.40 Mn |
| Mar 31, 2025 | 7.86 Mn |
| Dec 31, 2024 | 3.13 Mn |
| Sep 30, 2024 | 2.60 Mn |
| Jun 30, 2024 | 477,000.00 |
| Dec 31, 2023 | 1.97 Mn |